Posts Tagged ‘Relmada Therapeutics’
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $100 Million At-The-Market Offering Facility
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $172.5 Million Upsized Public Offering Underwritten by Goldman Sachs and Jefferies
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in $75 Million At-The-Market Offering
Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock
Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing
Press Release – New York, NY – October 15, 2019 – Sichenzia Ross Ference LLP founding partner Gregory Sichenzia will join representatives of client Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical stage, specialty pharmaceutical company, focused on treatment solutions for depression, CNS and ophthalmological disorders, at the Nasdaq MarketSite in Times Square to ring the October…
Read MoreSichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting
New York, NY – October 10, 2019 – Sichenzia Ross Ference LLP announced today that the firm represented Relmada Therapeutics, Inc. (NASDAQ: RLMD), in the Company’s up-listing to the NASDAQ Capital Market. The Sichenzia Ross Ference LLP team was led by Gregory Sichenzia and partner Barrett DiPaolo. The up-listing is effective for trading on October…
Read More
